Nucleic Acid Therapeutics CDMO Market - Industry Analysis, Trends & Forecast 2030 | BIS Research

1
Nucleic Acid Therapeutics CDMO Market - A
Global and Regional Analysis
res tion
https//pixabay.com/photos/tire-rim-car-mechanic-1
14259/
Table of Content
Attribu
t e k r a M O M D C s c i t u e p a r
e h T d i c A c i
Focus on Product, Technology, and End
User Analysis and Forecast 2021-2030 September
2021
e l c u 1 N All rights reserved at BIS
Research Inc.
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
Nucleic Acid Therapeutics CDMO Market
Copyright 2021 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting, or otherwise reproducing
any or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered whether for sale or
otherwise to any third party.
2
3

• Table of Content
• Executive Summary ................................
  ........................................ 18
• Research Methodology .............................
  ...................................... 24
• 1. Markets........................................
  ............................................ 29
• 1.1 Industry Outlook .............................
  ..................................................
  ...............30
• 1.1.1 Global Nucleic Acid Therapeutics CDMO
  Market Overview ....................30
  1.2 Product Definition............................
  ..................................................
  ..............30
• Global Nucleic Acid Therapeutics CDMO Market
  Footprint, ( Million),
• 2020-2030.........................................
  ..................................................
  ...............30
• Current Nucleic Acid Therapeutic CDMOs Landscape
  ................................32
• Significant Usage of Nucleic Acid in Therapeutics
  ......................................33
• Types of Nucleic Acid Synthesized for
  Therapeutics...................................34
• Anti-Sense Oligonucleotides (ASOs) and DNA
  Aptamers .......................34
• RNA interference RNAi and short interfering
  RNAs siRNAs ..............34 1.6.3 MicroRNAs
  ..................................................
  .................................................3
  4 1.6.4 RNA Aptamers and RNA Decoys
  ..................................................
  .............35 1.6.5 Ribozymes
  ..................................................
  .................................................3
  5 1.6.6 Circular RNAs ...........................
  ..................................................
  .................35 1.7 Market Dynamics
  ..................................................
  ...........................................35
  1.7.1 Market Drivers .............................
  ..................................................
  ..............36
• Accelerating Shift of the Pharmaceutical Market
  Toward Innovative Biologic and Cell and Gene
  Therapy Products .................................
  ................ 36
• Reduction in Overall Manufacturing Cost at CDMOs
  ........................................ 37
  1.7.1.3 Rising Approvals of Nucleic Acid
  Therapeutics......................................
  ........... 38 1.7.2 Restraints..................
  ..................................................
  .................................40 1.7.2.1 Lack
  of Expertise in Nucleic Acid Manufacturing
  .............................................. 40
  1.7.2.2 Supply Chain and Logistical
  Challenges........................................
  ................... 40
• 3

Nucleic Acid Therapeutics CDMO Market
4

• 1.7.2.3 Difficult Therapeutic Classification Due
  to Wide Variety of Nucleic Acids ......... 41
• 1.7.3 Opportunities ............................
  ..................................................
  .................41
• Increasing Outsourcing Trend Among Pharmaceutical
  Companies .................. 41
• Accelerating Research and Development Along with
  Technology .................... 42
  1.7.3.3 Growth in Developing Countries
  ..................................................
  ..................... 42
• 2. Competitive Landscape .........................
  ................................... 43
• 2.1 New Offerings and Funding and
  Investments.......................................
  ........44 2.2 Regulatory and Legal
  ..................................................
  ....................................44
• 2.3 Mergers and Acquisitions .....................
  ..................................................
  ........44
• 2.4 Synergistic Activities .......................
  ..................................................
  .............45
• 2.5 Market Share Analysis ........................
  ..................................................
  ..........45
• 2.6 Growth Share Analysis.........................
  ..................................................
  .........46
• 3. Chemical Synthesis Method .....................
  ................................ 49
• 3.1 Overview......................................
  ..................................................
  ...................50
• 3.1.1 Solid-Phase Oligonucleotide Synthesis
  ..................................................
  ..51
• 3.1.1.1 Advantages and Challenges of
  SPOS..............................................
  ................ 51
• 3.1.1.2 Method....................................
  ..................................................
  ....................... 52
• 3.1.1.2.1 Deprotecting/Detritylation..............
  ..................................................
  ......................... 52
• 3.1.1.2.2 Coupling ...............................
  ..................................................
  .................................. 52

Nucleic Acid Therapeutics CDMO Market
5
4.1.2 Microarray-Based Method ....................
..................................................
....57 5. End-User ...............................
..................................................
59 5.1 Overview..................................
..................................................
.......................60 5.1.1 Pharmaceutical
Companies.........................................
...............................60 5.1.2
Academic Research Institute ......................
...............................................61
5.1.3 Diagnostic Laboratories
..................................................
...........................62 6. Products
..................................................
................................ 64 6.1 Global
Nucleic Acid Therapeutics CDMO Market (by
Product) ...................65 6.1.1 Standard
Nucleic Acid .....................................
...........................................66
6.1.2 Micro-Scale Nucleic Acid ...................
..................................................
.......68 6.1.3 Large-Scale Nucleic
Acid..............................................
..............................69 6.1.4 Custom
Nucleic Acid......................................
.............................................70
6.1.5 Modified Nucleic Acid ......................
..................................................
.........71 6.1.6 Primers .......................
..................................................
................................72 6.1.7 Probes
..................................................
..................................................
......73 6.1.8 Other Nucleic Acid
..................................................
....................................74 6.1.9
Other Services ...................................
..................................................
........75 7. Regions ............................
..................................................
..... 77 7.1 Overview.............................
..................................................
............................78 7.2 North America
..................................................
................................................80
7.2.1 U.S. ....................................
..................................................
.........................82 7.2.2 Canada
..................................................
..................................................
.....83 7.3 Europe ...............................
..................................................
.............................85 7.3.1
Germany...........................................
..................................................
..........86 7.3.2 U.K. ........................
..................................................
.....................................87 7.3.3
France............................................
..................................................
.............88 7.3.4 Italy ....................
..................................................
.........................................89
Nucleic Acid Therapeutics CDMO Market
6
7.3.5 Spain......................................
..................................................
.....................90 7.3.6 Rest-of-Europe.....
..................................................
......................................91 7.4 Asia-
Pacific ..........................................
..................................................
..........93 7.4.1 China .......................
..................................................
...................................94 7.4.2
India ............................................
..................................................
................95 7.4.3 Japan
..................................................
..................................................
........96 7.4.4 Australia .....................
..................................................
................................97 7.4.5
Rest-of-Asia-Pacific..............................
..................................................
.....98 7.5 Rest-of-the-World ....................
..................................................
......................99 8. Markets -
Competitive Benchmarking Company Profiles......
100 8.1 Company Profile ..........................
..................................................
................101 8.2 Agilent Technologies,
Inc. .............................................
...............................102 8.2.1
Company Overview .................................
..................................................
102 8.2.2 Role of Agilent Technologies, Inc. in
the Global Nucleic Acid Therapeutics CDMO
Market............................................
..........................102 8.2.3
Financials........................................
..................................................
.........104 8.2.4 Key Insights About Financial
Health of the Company ...........................1
07 8.2.5 SWOT Analysis ..........................
..................................................
..............108 8.3 Ajinomoto Co. Inc.
..................................................
.......................................109 8.3.1
Company Overview .................................
..................................................
109 8.3.2 Role of Ajinomoto Co. Inc. in Global
Nucleic Acid Therapeutics CDMO Market
..................................................
...........................................109 8.3
.3 Financials...................................
..................................................
..............110 8.3.4 SWOT Analysis
..................................................
........................................112 8.4 Ba
chem Holding AG. .................................
..................................................
..113 8.4.1 Company Overview .....................
..................................................
............113
Nucleic Acid Therapeutics CDMO Market
7
8.4.2 Role of Bachem Holding AG. in Global
Nucleic Acid Therapeutics CDMO Market
..................................................
...........................................113 8.4
.3 SWOT Analysis ...............................
..................................................
.........114 8.5 Biospring GmbH
..................................................
..........................................115 8.5.
1 Company Overview .............................
..................................................
....115 8.5.2 Role of Biospring GmbH in Global
Nucleic Acid Therapeutics CDMO
Market............................................
..................................................
...........115 8.5.3 SWOT Analysis
..................................................
........................................116 8.6 Co
rden Pharma International.........................
...............................................117
8.6.1 Company Overview ........................
..................................................
.........117 8.6.2 Role of Corden Pharma
International in the Global Nucleic Acid
Therapeutics CDMO Market..........................
............................................117 8.
6.3 SWOT Analysis ..............................
..................................................
..........119 8.7 Danaher Corporation
..................................................
...................................120 8.7.1
Company Overview .................................
..................................................
120 8.7.2 Role of Danaher Corporation in the Glob
al Nucleic Acid Therapeutics CDMO
Market............................................
..........................120 8.7.3
Financials........................................
..................................................
.........121 8.7.4 Key Insights About Financial
Health of the Company ...........................1
24 8.7.5 SWOT Analysis ..........................
..................................................
..............125 8.8 Guangzhou Ruibo
Biotechnology Co., Ltd............................
......................126 8.8.1 Company Overview
..................................................
.................................126 8.8.2 Role
of Guangzhou Ruibo Biotechnology Co., Ltd. in the
Global Nucleic Acid Therapeutics CDMO Market
...............................................126
8.8.3 SWOT Analysis ...........................
..................................................
.............128 8.9 KNC Laboratories Co., Ltd.
..................................................
.........................129 8.9.1 Company
Overview .........................................
..........................................129
Nucleic Acid Therapeutics CDMO Market
8
8.9.2 Role of KNC Laboratories Co., Ltd. in the
Global Nucleic Acid Therapeutics CDMO
Market............................................
..........................129 8.9.3
Financials........................................
..................................................
.........130 8.9.4 SWOT Analysis
..................................................
........................................131 8.10 L
GC Limited .......................................
..................................................
..........132 8.10.1 Company Overview
..................................................
.................................132 8.10.2 Role
of LGC Limited in the Global Nucleic Acid
Therapeutics CDMO Market.........................
..................................................
..............................132 8.10.3
Financials........................................
..................................................
.........133 8.10.4 Key Insights About Financial
Health of the Company ...........................1
34 8.10.5 SWOT Analysis .........................
..................................................
...............135 8.11 Merck KGaA
..................................................
.................................................1
36 8.11.1 Company Overview ......................
..................................................
...........136 8.11.2 Role of Merck KGaA in the
Global Nucleic Acid Therapeutics CDMO
Market............................................
..................................................
...........136 8.11.3 Financials..................
..................................................
...............................137 8.11.4 Key
Insights About Financial Health of the Company
...........................140 8.11.5 SWOT
Analysis .........................................
.................................................1
41 8.12 Nippon Shokubai Co., Ltd.
..................................................
..........................142 8.12.1 Company
Overview .........................................
..........................................142 8.12
.2 Role of Nippon Shokubai Co., Ltd. in the
Global Nucleic Acid Therapeutics CDMO
Market............................................
..........................142 8.12.3
Financials........................................
..................................................
.........143 8.12.4 Key Insights About Financial
Health of the Company ...........................1
44 8.12.5 SWOT Analysis .........................
..................................................
...............145 8.13 Nitto Denko Avecia Inc.
..................................................
...............................146 8.13.1
Company Overview .................................
..................................................
146
Nucleic Acid Therapeutics CDMO Market
9
8.13.2 Role of Nitto Denko Avecia Inc. in the
Global Nucleic Acid Therapeutics CDMO
Market............................................
..........................146 8.13.3 SWOT
Analysis .........................................
.................................................1
48 8.14 QIAGEN N.V................................
..................................................
..................149 8.14.1 Company Overview
..................................................
.................................149 8.14.2 Role
of QIAGEN N.V. in the Global Nucleic Acid
Therapeutics CDMO Market.........................
..................................................
..............................149 8.14.3
Financials........................................
..................................................
.........150 8.14.4 Key Insights About Financial
Health of the Company ...........................1
52 8.14.5 SWOT Analysis .........................
..................................................
...............153 8.15 ST Pharm Co
Ltd...............................................
.............................................154
8.15.1 Company Overview ..........................
..................................................
.......154 8.15.2 Role of ST Pharm Co Ltd in
Global Nucleic Acid Therapeutics CDMO Market
..................................................
...........................................154 8.1
6 Sumitomo Chemical Co., Ltd. ....................
..................................................
.156 8.16.1 Company Overview .....................
..................................................
............156 8.16.2 Role of Sumitomo Chemical
Co., Ltd. in the Global Nucleic Acid
Therapeutics CDMO Market..........................
............................................156 8.
16.3 Financials...................................
..................................................
..............158 8.16.4 Key Insights About
Financial Health of the Company
...........................160 8.16.5 SWOT
Analysis .........................................
.................................................1
61 8.17 Syngene International Limited............
..................................................
........162 8.17.1 Company Overview
..................................................
.................................162 8.17.2 Role
of Syngene International Limited in the Global
Nucleic Acid Therapeutics CDMO
Market............................................
..........................162 8.17.3
Financials........................................
..................................................
.........163 8.17.4 Key Insights About Financial
Health of the Company ...........................1
64 8.17.5 SWOT Analysis .........................
..................................................
...............165
Nucleic Acid Therapeutics CDMO Market
10
8.18 Thermo Fisher Scientific Inc.................
..................................................
......166 8.18.1 Company Overview
..................................................
.................................166 8.18.2 Role
of Thermo Fisher Scientific Inc. in the Global
Nucleic Acid Therapeutics CDMO
Market............................................
..........................166 8.18.3
Financials........................................
..................................................
.........167 8.18.4 Key Insights About Financial
Health of the Company ...........................1
69 8.18.5 SWOT Analysis .........................
..................................................
...............170 8.19 Wuxi AppTec
..................................................
................................................17
1 8.19.1 Company Overview .......................
..................................................
..........171 8.19.2 Role of Wuxi AppTec in the
Global Nucleic Acid Therapeutics CDMO Market
..................................................
...........................................171 8.1
9.3 Financials....................................
..................................................
.............172 8.19.4 Key Insights About
Financial Health of the Company
...........................174 8.19.5 SWOT
Analysis .........................................
.................................................1
75 8.20 Yamasa Corporation........................
..................................................
............176 8.20.1 Company Overview
..................................................
.................................176 8.20.2
Role of Yamasa Corporation in the Global Nucleic A
cid Therapeutics CDMO Market.....................
.................................................1
76 8.20.3 SWOT Analysis ..........................
..................................................
..............178
Nucleic Acid Therapeutics CDMO Market
11
List of Figures
Figure 1 Figure 2 Figure 3 Figure 4
Global Nucleic Acid Therapeutics CDMO Market,
Realistic and Optimistic Scenario, Million
Global Nucleic Acid Therapeutics CDMO Market,
Market Dynamics Share of Key Market Strategies
and Developments, July 2017-July 2021 Growth
Share Matrix for Global Nucleic Acid Therapeutics
CDMO Market (by Company), 2019-2020 Global
Nucleic Acid Therapeutics CDMO Market Research
Methodology Primary Research Methodology Global
Nucleic Acid Therapeutics CDMO Market, Million,
2020-2030 Optimistic View of Global Nucleic Acid
Therapeutics CDMO Market, Million Overview of
CRO and CDMO Services
Figure 5 Figure 6 Figure 7 Figure 8 Figure 9
Figure 10 Global Nucleic Acid Therapeutics CDMO
Market, Market Dynamics Figure 11 Deal Value of
Mergers and Acquisitions Involving Cell and Gene
Therapies (2016-2019) Figure 12 Share of Key
Market Strategies and Developments, July
2017-July 2021 Figure 13 Share of Mergers and
Acquisitions (by Company), 2017-2021 Figure 14
Share of Synergistic Activities (by Company),
2017-2021 Figure 15 Market Share Analysis for
Global Nucleic Acid Therapeutics CDMO Market,
2020 Figure 16 Growth Share Matrix for Global
Nucleic Acid Therapeutics CDMO Market
(by Company),2019- 2020 Figure 17 Global Nucleic
Acid Therapeutics CDMO Market (by Chemical
Synthesis Method) Figure 18 Share of Global
Nucleic Acid Therapeutics CDMO Market (by
Chemical Synthesis Method), 2020 and 2030 Figure
19 Solid-Phase Oligonucleotide Synthesis Market
Size and Forecast Figure 20 Liquid-Phase
Oligonucleotide Synthesis Market Size and
Forecast Figure 21 Share of Global Nucleic Acid
Therapeutics CDMO Market (by Technology), 2020
and 2030 Figure 22 Global Nucleic Acid
Therapeutics CDMO Market (by Column-Based
Method), 2020-2030 Figure 23 Global Nucleic
Acid Therapeutics CDMO Market (by
Microarray-Based Method), 2020-2030 Figure 24
Global Nucleic Acid Therapeutics CDMO Market, by
End User, 2020 and 2030 (Million) Figure 25
Global Nucleic Acid Therapeutics CDMO Market, by
Pharmaceutical and Biotechnology Companies Figure
26 Global Nucleic Acid Therapeutics CDMO Market,
by Academic Research Institutes Figure 27 Global
Nucleic Acid Therapeutics CDMO Market, by
Diagnostic Laboratories Figure 28 Global
Nucleic Acid Therapeutics CDMO Market (by
Product) Figure 29 Share of Global Nucleic Acid
Therapeutics CDMO Market (by Product), 2020 and
2030 (Million) Figure 30 Global Nucleic Acid
Therapeutics CDMO Market, by Standard Nucleic
Acid Figure 31 Global Nucleic Acid Therapeutics
CDMO Market, by Micro-Scale Nucleic Acid Figure
32 Global Nucleic Acid Therapeutics CDMO Market,
by Large-Scale Nucleic Acid Market 11
Nucleic Acid Therapeutics CDMO Market
12
Figure 33 Global Nucleic Acid Therapeutics CDMO
Market, by Custom Nucleic Acid Figure 34 Global
Nucleic Acid Therapeutics CDMO Market, by
Modified Nucleic Acid Figure 35 Global Nucleic
Acid Therapeutics CDMO Market Primer Market, by
Primers Figure 36 Global Nucleic Acid
Therapeutics CDMO Market, by Primer Figure 37
Global Nucleic Acid Therapeutics CDMO Market, by
Others NA Figure 38 Global Nucleic Acid
Therapeutics CDMO Market, Other Services Figure
39 Global Nucleic Acid Therapeutics CDMO Market
(by Region), Million Units, 2020-2030 Figure 40
Share of North America Nucleic Acid Therapeutics
CDMO Market Revenue (by Country), 2020-2030,
Million Figure 41 North America Market
Dynamics Figure 42 U.S. Nucleic Acid
Therapeutics CDMO Market, 2020-2030, Million
Figure 43 Canada Nucleic Acid Therapeutics CDMO
Market, 2020-2030, Million Figure 44 Share of
Europe Nucleic Acid Therapeutics CDMO Market (by
Country), 2020-2030, Million Figure 45 Europe
Market Dynamics Figure 46 Germany Nucleic Acid
Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 47 U.K. Nucleic Acid
Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 48 France Nucleic Acid
Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 49 Italy Nucleic Acid
Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 50 Spain Nucleic Acid
Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 51 Rest-of-Europe Nucleic Acid
Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 52 APAC Market Dynamics Figure
53 Asia-Pacific Nucleic Acid Therapeutics CDMO
Market Revenue (by Country), 2020-2030, Million F
igure 54 China Nucleic Acid Therapeutics CDMO
Market Revenue, 2020-2030, Million Figure 55
India Nucleic Acid Therapeutics CDMO Market
Revenue, 2020-2030, Million Figure 56 Japan
Nucleic Acid Therapeutics CDMO Market Revenue,
2020-2030, Million Figure 57 Australia Nucleic
Acid Therapeutics CDMO Market Revenue, 2020-2030,
Million Figure 58 Rest-of-Asia-Pacific Nucleic
Acid Therapeutics CDMO Market Revenue,
2020-2030, Million Figure 59 Rest-of-the-World
Nucleic Acid Therapeutics CDMO Market Revenue,
2020-2030, Million Figure 60 Shares of Key
Company Profiles Figure 61 Agilent Technologies,
Inc. Product Portfolio Figure 62 Agilent
Technologies, Inc. Overall Financials, 2018-2020
Figure 63 Agilent Technologies, Inc. Revenue
(by Segment), 2018-2020 Figure 64 Agilent
Technologies, Inc. Revenue (by Region),
2018-2020 Figure 65 Agilent Technologies, Inc.
RD Expenditure, 2018-2020 Figure 66 Agilent
Technologies, Inc. SWOT Analysis Figure 67
Ajinomoto Co. Inc, Overall Product Portfolio 12
Nucleic Acid Therapeutics CDMO Market
13
Figure 68 Ajinomoto Co., Inc. Overall
Financials, 2017-2019 Figure 69 Ajinomoto Co.,
Inc. Revenue (by Segment), 2017-2019 Figure 70
Ajinomoto Co., Inc. SWOT Analysis Figure 71
Bachem Holding AG. Overall Product Portfolio
Figure 72 Bachem Holding AG. SWOT
Analysis Figure 73 Biospring GmbH Overall
Product Portfolio Figure 74 Biospring GmbH
SWOT Analysis Figure 75 Corden Pharma
International Overall Product Portfolio Figure
76 Corden Pharma International SWOT
Analysis Figure 77 Danaher Corporation Product
Portfolio Figure 78 Danaher Corporation Overall
Financials, 2018-2020 Figure 79 Danaher
Corporation Revenue (by Segment),
2018-2020 Figure 80 Danaher Corporation Revenue
(by Region), 2018-2020 Figure 81 Danaher
Corporation RD Expenditure, 2018-2020 Figure
82 Danaher Corporation SWOT Analysis Figure 83
Guangzhou Ruibo Biotechnology Co., Ltd. Product
Portfolio Figure 84 Guangzhou Ruibo
Biotechnology Co., Ltd SWOT Analysis Figure 85
KNC Laboratories Co., Ltd. Overall Product
Portfolio Figure 86 KNC Laboratories Co., Ltd.
Overall Financials, 2018-2020 Figure 87 KNC
Laboratories Co., Ltd. SWOT Analysis Figure 88
LGC Limited Overall Product Portfolio Figure
89 LGC Limited Overall Financials,
2018-2020 Figure 90 LGC Limited Revenue (by
Segment), 2018-2020 Figure 91 LGC Limited RD
Expenditure, 2018-2020 Figure 92 LGC Limited
SWOT Analysis Figure 93 Merck KGaA Product
Portfolio Figure 94 Merck KGaA Overall
Financials, 2018-2020 Figure 95 Merck KGaA
Revenue (by Segment), 2018-2020 Figure 96 Merck
KGaA Revenue (by Region), 2018-2020 Figure 97
Merck KGaA RD Expenditure, 2018-2020 Figure
98 Merck KGaA SWOT Analysis Figure 99 Nippon
Shokubai Co., Ltd. Overall Financials, 2018-2020
Nucleic Acid Therapeutics CDMO Market
Figure 100 Figure 101 Figure 102 Figure
103 Figure 104 Figure 105 Figure 106
Nippon Shokubai Co., Ltd Revenue (by Segment),
2018-2020 Nippon Shokubai Co., Ltd RD
Expenditure, 2018-2020 Nippon Shokubai Co., Ltd
SWOT Analysis Nitto Denko Avecia Inc. Product
Portfolio Nitto Denko Avecia Inc. SWOT Analysis
QIAGEN N.V. Product Portfolio QIAGEN N.V.
Overall Financials, 2018-2020
14
Figure 107 Figure 108 Figure 109 Figure
110 Figure 111 Figure 112 Figure 113 Figure
114 Figure 115 Figure 116 Figure 117 Figure
118 Figure 119 Figure 120 Figure 121 Figure
122 Figure 123 Figure 124 Figure 125 Figure
126 Figure 127 Figure 128 Figure 129 Figure
130 Figure 131 Figure 132 Figure 133 Figure
134 Figure 135 Figure 136
QIAGEN N.V. Revenue (by Segment), 2018-2020
QIAGEN N.V. Revenue (by Region), 2018-2020
QIAGEN N.V. RD Expenditure, 2018-2020 QIAGEN
N.V. SWOT Analysis ST Pharm Co Ltd Overall
Product Portfolio ST Pharm Co Ltd SWOT
Analysis Sumitomo Chemical Co., Ltd. Overall
Product Portfolio Sumitomo Chemical Co., Ltd
Overall Financials, 2018-2020 Sumitomo Chemical
Co., Ltd. Revenue (by Segment),
2018-2020 Sumitomo Chemical Co., Ltd RD
Expenditure, 2018-2020 Sumitomo Chemical Co.,
Ltd. SWOT Analysis Syngene International
Limited Overall Product Portfolio Syngene
International Limited Overall Financials,
2018-2020 Syngene International Limited Revenue
(by Region), 2018-2020 Syngene International
Limited RD Expenditure, 2018-2020 Syngene
International Limited SWOT Analysis Thermo
Fisher Scientific Inc. Product Portfolio Thermo
Fisher Scientific, Inc. Overall Financials,
2018-2020 Thermo Fisher Scientific Inc. Revenue
(by Segment) 2018-2020 Thermo Fisher Scientific
Inc. Revenue (by Region), 2018-2020 Thermo
Fisher Scientific Inc. RD Expenditure,
2018-2020 Thermo Fisher Scientific Inc. SWOT
Analysis Wuxi AppTec Overall Product
Portfolio Wuxi AppTec Overall Financials,
2018-2020 Wuxi AppTec Revenue (by Segment),
2018-2020 Wuxi AppTec Revenue (by Region),
2018-2020 Wuxi AppTec RD Expenditure, 2018-2020
Wuxi AppTec SWOT Analysis Yamasa Corporation
Overall Product Portfolio Yamasa Corporation
SWOT Analysis
Nucleic Acid Therapeutics CDMO Market
15
List of Tables
Table 1 Table 2 Table 3 Table 4 Table
5 Table 6 Table 7 Table 8 Table 9 Table
10 Table 11
Oligonucleotide Therapies Approved by the FDA
Nucleic Acid Therapies Approved by FDA and EMA
Companies offering Standard Nucleic Acid
Companies offering Micro-Scale Nucleic Acid
Companies offering Large-Scale Nucleic Acid
Companies offering Custom Nucleic Acid Companies
offering Modified Nucleic Acid Companies
offering Primers Companies offering
Probes Companies offering Other NA Companies
offering Other Services
Nucleic Acid Therapeutics CDMO Market
16
Disclaimer BIS Research Inc. provides valuable
market intelligence to an exclusive group of
customers in response to orders. The report is
licensed for the customer's internal use only and
is subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium
or in any form for any purpose, without the
express written consent of BIS Research Inc.
Customer will not disclose the contents of the
report, whether directly in any media or
indirectly through incorporation in a database,
marketing list, report or otherwise, or use or
permit the use of Information to generate any
statistical or other information that is or will
be provided to third parties or voluntarily
produce Information in legal proceedings. Marke
t reports are based on expectations, estimates
and projections as of the date such information
is available. Any recommendation contained in
this report may not be suitable for all investors
or businesses. The market conclusions drawn are
necessarily based upon a number of estimates and
assumptions that, while considered reasonable by
BIS Research Inc. as of the date of such
statements, are inherently subject to market
fluctuations and business, economic and
competitive uncertainties and contingencies For
more details regarding permission, please contact
us Email sales_at_bisresearch.com Tel [phone]
8135
Nucleic Acid Therapeutics CDMO Market
17
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
hello_at_bisresearch.com Call Us 1-510-404-8135
t e k r a M O M D C s c i t u e p a r
e h T d i c A c i e l c u 17 N All
rights reserved at BIS Research Inc.
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel [phone]
www.bisresearch.com